Prevention strategies for type 1 diabetes

Reviews in Endocrine and Metabolic Disorders

Volumn 7, Issue 3, 2006, Pages 215-224

  Kishiyama, Christopher M ^a   Chase, H Peter ^a   Barker, Jennifer M ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

Autoimmunity; Genetics; Immunology; Prevention; Therapy; Type 1 diabetes

Indexed keywords

AZATHIOPRINE; BCG VACCINE; C PEPTIDE; C REACTIVE PROTEIN; CYCLOSPORIN A; CYTOKINE; DACLIZUMAB; DOCOSAHEXAENOIC ACID; GLUCOCORTICOID; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; HEAT SHOCK PROTEIN 60; HEMOGLOBIN A1C; INSULIN; INSULIN ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 4; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; OKT 3; PLACEBO; PREDNISONE; PROSTAGLANDIN; RITUXIMAB; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA;

ANTIBODY PRODUCTION; ARTHRALGIA; AUTOIMMUNITY; BREAST FEEDING; CHILD NUTRITION; CHILDHOOD DISEASE; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIABETES CONTROL; DRUG FEVER; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GASTROINTESTINAL SYMPTOM; GENETIC RISK; GENOTYPE; HAIR LOSS; HIGH RISK INFANT; HLA SYSTEM; HUMAN; HYPOTENSION; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; IMPAIRED GLUCOSE TOLERANCE; INFANT NUTRITION; INSULIN DEPENDENT DIABETES MELLITUS; INTRAVENOUS GLUCOSE TOLERANCE TEST; LYMPHOCYTOPENIA; MICROALBUMINURIA; MOON FACE; MYALGIA; NEPHROTOXICITY; NONHUMAN; NONOBESE DIABETIC MOUSE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET CELL; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; SIDE EFFECT; THROMBOCYTOPENIA;

AUTOIMMUNITY; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 1; HUMANS; MODELS, BIOLOGICAL; NUTRITION PHYSIOLOGY; PREVENTIVE MEDICINE; TIME FACTORS;

EID: 33846088775     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11154-006-9015-z     Document Type: Review

References (64)

1. Onkamo P, Vaananen S, Karvonen M, Tuomilehto J. Worldwide increase in incidence of type 1 diabetes - the analysis of the data on published incidence trends. Diabetologia 2000;43:1334-6.
2. Komulainen J, Kulmala P, Savola K, Lounamaa R, Ilonen J, Reijonen H, et al. Clinical, autoimmune, and genetic characteristics of very young children with type 1 diabetes. Childhood diabetes in Finland (DiMe) study group. Diabetes Care 1999;22 12:1950-5 (Dec).
3. Kulmala P, Savola K, Reijonen H, Veijola R, Vahasalo P, Karjalainen J, et al. Genetic markers, humoral autoimmunity, and prediction of type 1 diabetes in siblings of affected children. Childhood diabetes in Finland study group. Diabetes 2000;49 1:48-58, Jan.
4. EURODIAB ACE Study Group. Lancet 2000;355:873-6.
5. Pilcher CC, Dickens K, Elliott RB. ICA only develop in early childhood. Diabetes Res Clin Pract 1991;14:S82 (Abstract).
6. Bach J-F. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911-20.
7. McKinney PA, Okasha M, Parslow RC, Law GR, Gurney KA, Williams R, et al. Early social mixing and childhood type 1 diabetes mellitus: a case-control study in Yorkshire, UK. Diabet Med 2000;17:236-42.
8. Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Childhood vaccination and type 1 diabetes. N Engle J Med 2004;350:1398-404.
9. Rewers M, Norris J, Kretowski A. Chapter 9: Epidemiology of type 1 diabetes. In: Eisenthbarth GS, editor. Immunology of type 1 diabetes. 2nd ed. Kluwer: Dordrecht; 2005 (Academic/Plenum).
10. Menser MA, Forrest JM, Bransby RD. Rubella infection and diabetes mellitus. Lancet 1978;1:57-60.
11. Yoon J-W, Austin M, Onodera T, Notkins AL. Virus-induced diabetes mellitus: isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 1979;300:1173-9.
12. Lonnrot M, Korpela K, Knip M, Ilonen J, Simell O, Korhonen S, et al. Enterovirus infection as a risk factor for β-Cell autoimmunity in a prospectively observed birth cohort. Diabetes 2000;49:1314-8.
13. Honeyman MC, Coulson BS, Stone NL, Gellert SA, Goldwater PN, Steele CE, et al. Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing type 1 diabetes. Diabetes 2000;49:1319-24.
14. Graves PM, Norris JM, Pallansch MA, Gerling IV, Rewers M. The role of enteroviral infections in the development of IDDM. Diabetes 1997;46:161-8.
15. Elliott RB, Martin JM. Dietary protein: a trigger of insulin-dependent diabetes in the BB rat? Diabetologia 1984;26:297-9.
16. Karges W, Hammond-McKibben D, Cheung RK, Visconti M, Shibuya N, Kemp D, et al. Immunological aspects of nutritional diabetes prevention in NOD mice. A pilot study for the cow's milk-based IDDM Prevention Trial. Diabetes 1997;46:557-64.
17. Gerstein H. Cow's milk exposure and type 1 diabetes mellitus. Diabetes Care 1994;17:13-9.
18. Norris JM, Beaty B, Klingensmith GJ, Yu L, Hoffman M, Chase HP, et al. Lack of association between early exposure to cow's milk protein and β-cell autoimmunity. JAMA 1996;276:609-14.
19. Couper JJ, Steele C, Beresford S, Powell T, McCaul K, Pollard A, et al. Lack of association between duration of breast-feeding or introduction of cow's milk and development of islet autoimmunity. Diabetes 1999;48:2145-9.
20. Paronen J, Knip M, Savilahti E, Virtanen SM, Ilonen J, Akerblom HK, et al. Effect of cow's milk exposure and maternal type 1 diabetes on cellular and humoral immunization to dietary insulin in infants at genetic risk for type 1 diabetes. Diabetes 2000;49:1657-65.
21. Ziegler A-G, Hummel M, Sckenker M, Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB study. Diabetes 1999;48:460-8.
22. Simopoulos AP. Essential fatty acids in health and chronic disease. Am J Clin Nutr 1999;70:560S-9S.
23. Stene LC, Ulriksen J, Magnus P, Joner G. Use of cod liver oil during pregnancy associated with lower risk of Type I diabetes in the offspring. Diabetologia 2000;43:1093-8.
24. Stene LC, Joner G, the Norwegian Childhood Diabetes Study Group. Use of cod liver oil in the first year of life associated with lower risk of childhood onset type 1 diabetes: a large population based case-control study. Am J Clin Nutr 2003;78:1128-34.
25. Joner G. The epidemiology of insulin-dependent diabetes mellitus in Norway: incidence, prevalence, microvascular complications and mortality (Thesis). Oslo: Haukeland University Hospital and Aker University Hospital; 1992.
26. Decsi T, Minda H, Hermann R, Kozári A, Erhardt E, Burus I, et al. Polyunsaturated fatty acids in plasma and erythrocyte membrane lipids of diabetic children. Prostaglandins Leukot Essent Fat Acids 2002;67:203-10.
27. Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, van der eer JW, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989;320:265-71.
28. Chase HP, Williams RL, Dupont J. Increased prostaglandin synthesis in childhood diabetes mellitus. J Pediatr 1979;94:185-9.
29. Litherland SA, She JX, Schatz D, Fuller K, Hutson AD, Peng RH, et al. Aberrant monocyte prostaglandin synthase 2 (PGS2) expression in type 1 diabetes before and after disease onset. Pediatr Diabetes 2003;4 1:10-8.
30. Halminen M, Simell O, Knip M, Ilonen J. Cytokine expression in unstimulated PBMC of children with type 1 diabetes and subjects positive for diabetes-associated autoantibodies. Scand J Immunol 2001;53:510-3.
31. Chase HP, Cooper S, Osberg I, Stene LC, Barriga K, Norris J, et al. Elevated C-Reactive protein levels in the development of type 1 diabetes. Diabetes 2004;53:2569-73.
32. McGregor JA, Allen KG, Harris MA, Reece M, Wheeler M, French JI, et al. The omega-3 story: nutritional prevention of preterm birth and other adverse pregnancy outcomes. Obstet Gynecol Surv 2001;56 5 Suppl 1:S1-13.
33. Christensen OB, Hindsen M, Svensson A. Natural history of dermatitis herpetiformis in southern Sweden. Dermatologica 1986;173:271-7.
34. DPT-1 Study Group. The diabetes prevention trial-type 1 diabetes (DPT-1): implementation of screening and staging of relatives. Transplant Proc 1995;27:3377.
35. Rewers M, LaPorte RE, King H, Tuomilehto J. Trends in the prevalence and incidence of diabetes: insulin-dependent diabetes mellitus in childhood. World Health Stat Q 1985;41:179-89.
36. Patrick SL, Moy CS, LaPorte RE. The world of IDDM: what international epidemiologic studies reveal about the etiology and natural history of IDDM. Diabetes/Metab Rev 1989;5:571-8.
37. Steck AK, Barriga KJ, Emery LM, Fiallo-Scharer RV, Gottlieb PA, Rewers MJ. Secondary attack rate of type 1 diabetes in Colorado families. Diabetes Care 2005;28:296-300.
38. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 1991;88:10252-6.
39. Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci U S A 1996;93:956-60.
40. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-91.
41. Diabetes Prevention Trial-Type 1 Study Group[Gitelman SE - Study Group Member]. Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial-type 1. Diabetes Care 2005;28:1068-76.
42. Pociot F, ReimersJI, Andersen HU. Nicotinamide - biological actions and therapeutic potential in diabetes prevention. Diabetologia 1993;36:574-6.
43. Pozzilli P, Visalli N, Ghirlanda G, Manna R, Andreani D. Nicotinamide increases C-peptide secretion in patients with recent onset type 1 diabetes. Diabet Med 1989;6:568-72.
44. Gale EA, Bingley PJ, Emmett CL, Collier T. European nicotinamide diabetes intervention trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004;363:925-31.
45. Gepts W. Pathologica anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965;14:619-33.
46. Group TDC. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial: a randomized controlled trial. Ann Intern Med 1998;128:517-23.
47. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta cell function: report of an ADA workship, 21-22 October 2001. Diabetes 2004;51:2126-34.
48. Herold KC, Lancki DW, Moldwin RL, Fitch FW. Immunosuppressive effects of cyclosporine A on cloned T cells. J Immunol 1986;136:1315-21.
49. Rabinovich A. An update on cytokines in the pathogenesis of insulin-depended diabetes mellitus. Diabetes/Metab Rev 1998;14:129-51.
50. Stiller CR, Dupre J, Gent M, Jenner M, Keown PA, Laupacis A, et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellutis of recent onset. Science 1984;223:1362-7.
51. Bougneres PF, Carel JC, Castano L, Boitard C, Gardin JP, Landais P, et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 1988;318:663-70.
52. Parving HH, Tarnow L, Nielsen FS, Rossing P, Mandrup-Poulsen T, Osterby R, et al. Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. Diabetes Care 1999;22:478-83.
53. Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988;319:599-604.
54. Eisenbarth GS, Srikanta S, Jackson R, Rabinowe S, Dolinar R, Aoki T, et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res 1985;2:271-6.
55. Chatenoud L. OKT3-induced cytokine-release syndrome: prevention effect of anti-tumor necrosis factor monoclonal antibody. Transplant Proc 1993;25:47-51.
56. Chatenoud L, Bach JF. Anti-CD3 antibodies. Immunol Ser 1993;59:175-91.
57. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-8, May 30.
58. Chase HP, Hayward AR, Eisenbarth GS. Chapter 12, Clinical trials for the prevention of type I diabetes. In: Type I diabetes: molecular, cellular, and clinical immunology.
59. Qin HY, Sadelain MW, Hitchon C, Lauzon J, Singh B. Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice. J Immunol 1993;150:2072-80 (Mar 1).
60. Qin HY, Singh B. BCG vaccination prevents insulin-dependent diabetes mellitus (IDDM) in NOD mice after disease acceleration with cyclophosphamide. J Autoimmun 1997;10:271-8 (Jun).
61. Elias D, Prigozin H, Polak N, Rapoport M, Lohse AW, Cohen IR. Autoimmune diabetes induced by the beta-cell toxin STZ. Immunity to the 60-kDa heat shock protein and to insulin. Diabetes 1994;43:992-8.
62. Elias D, Cohen IR. Peptide therapy for diabetes in NOD mice. Lancet 1944;343:704-6.
63. Elias D, Reshef T, Birk OS, van der Zee R, Walker MD, Cohen IR. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc Natl Acad Sci U S A 199;88:3088-91.
64. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001;358 24:1749-53.